Lancet:曲美他嗪对PCI后心绞痛患者预后的影响

2020-08-31 MedSci原创 MedSci原创

心绞痛患者在成功接受经皮冠状动脉介入治疗后,服用曲美他嗪对心绞痛的复发或预后无显著改善作用

心绞痛患者在经皮冠状动脉介入治疗(PCI)后仍有较高的复发风险,且对于稳定型心绞痛患者PCI对患者预后的影响尚存在争议。曲美他嗪是一种常用抗心绞痛药物,可改善缺血心肌的能量代谢,有研究认为其对新接受PCI患者的预后和症状控制有益。近日研究人员评估了曲美他嗪对PCI患者长期预后的影响。
 
 
研究在欧洲、南美、亚洲和北非27个国家的365个中心开展,成功接受PCI治疗的患者参与。患者年龄为21-85岁,包含稳定型心绞痛、不稳定型心绞痛或非ST段抬高型心肌梗死患者,在入组前30天内接受PCI。患者随机接受35mg口服曲美他嗪治疗,每日两次或安慰剂。研究的主要疗效终点是心脏死亡、因心脏事件入院、心绞痛复发、改变,增加药物种类和剂量或需冠状动脉造影。
 
6007名患者参与研究,其中曲美他嗪组2998例,安慰剂组3009例。 中位随访47.5个月后,700名曲美他嗪组和714例安慰剂组患者出现终点事件(23.3% vs 23.7%,HR=0.98),组间主要终点事件发生率无显著差异。
曲美他嗪组2983名患者中有1219名(40.9%),安慰剂组2990名患者中有1230名(41.1%)出现严重治疗相关紧急不良事件。
 
研究认为,心绞痛患者在成功接受经皮冠状动脉介入治疗后,服用曲美他嗪对心绞痛的复发或预后无显著改善作用。
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830805, encodeId=bbfd183080556, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Nov 13 15:47:08 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769451, encodeId=ac4a1e69451bf, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 25 09:47:08 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692152, encodeId=edfc169215265, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 16 18:47:08 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881600, encodeId=931f88160088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 07:44:58 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881586, encodeId=f3e18815869b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=杀无敌战神, createdTime=Tue Sep 01 07:42:08 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033950, encodeId=984d10339501c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Aug 31 21:47:08 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
    2020-11-13 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830805, encodeId=bbfd183080556, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Nov 13 15:47:08 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769451, encodeId=ac4a1e69451bf, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 25 09:47:08 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692152, encodeId=edfc169215265, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 16 18:47:08 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881600, encodeId=931f88160088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 07:44:58 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881586, encodeId=f3e18815869b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=杀无敌战神, createdTime=Tue Sep 01 07:42:08 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033950, encodeId=984d10339501c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Aug 31 21:47:08 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830805, encodeId=bbfd183080556, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Nov 13 15:47:08 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769451, encodeId=ac4a1e69451bf, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 25 09:47:08 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692152, encodeId=edfc169215265, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 16 18:47:08 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881600, encodeId=931f88160088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 07:44:58 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881586, encodeId=f3e18815869b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=杀无敌战神, createdTime=Tue Sep 01 07:42:08 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033950, encodeId=984d10339501c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Aug 31 21:47:08 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1830805, encodeId=bbfd183080556, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Nov 13 15:47:08 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769451, encodeId=ac4a1e69451bf, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 25 09:47:08 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692152, encodeId=edfc169215265, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 16 18:47:08 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881600, encodeId=931f88160088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 07:44:58 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881586, encodeId=f3e18815869b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=杀无敌战神, createdTime=Tue Sep 01 07:42:08 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033950, encodeId=984d10339501c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Aug 31 21:47:08 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
    2020-09-01 14818eb4m67暂无昵称

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1830805, encodeId=bbfd183080556, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Nov 13 15:47:08 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769451, encodeId=ac4a1e69451bf, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 25 09:47:08 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692152, encodeId=edfc169215265, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 16 18:47:08 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881600, encodeId=931f88160088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 07:44:58 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881586, encodeId=f3e18815869b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=杀无敌战神, createdTime=Tue Sep 01 07:42:08 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033950, encodeId=984d10339501c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Aug 31 21:47:08 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
    2020-09-01 杀无敌战神

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1830805, encodeId=bbfd183080556, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Nov 13 15:47:08 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1769451, encodeId=ac4a1e69451bf, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Thu Feb 25 09:47:08 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692152, encodeId=edfc169215265, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Tue Mar 16 18:47:08 CST 2021, time=2021-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881600, encodeId=931f88160088, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64245268311, createdName=14818eb4m67暂无昵称, createdTime=Tue Sep 01 07:44:58 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=881586, encodeId=f3e18815869b, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200819/64fbd2072f9a45e4ab1d483ac903cef2/6094007d789849e39a3a1f25435a6f41.jpg, createdBy=72732561091, createdName=杀无敌战神, createdTime=Tue Sep 01 07:42:08 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033950, encodeId=984d10339501c, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Mon Aug 31 21:47:08 CST 2020, time=2020-08-31, status=1, ipAttribution=)]
    2020-08-31 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

相关资讯

EXCEL研究5年结果公布,CABG和PCI孰优孰劣?

《新英格兰医学杂志》(NEJM)发表的一项名为EXCEL的临床试验,从去年9月在美国TCT年会初步公布5年随访结果,到10月欧洲EACTS年会公开辩论,再到12月BBC曝光所谓“隐匿的真相

JAMA Intern Med:PCI策略与急性心肌梗死和心源性休克患者不良预后

近年来急性心肌梗死和心源性休克患者接受多血管经皮冠状动脉介入治疗的比例逐年增加,但相比于主要梗死血管PCI,多血管PCI后患者的不良预后率也显著增加

Lancet:新冠肺炎疫情对英国急性冠状动脉综合征患者入院治疗率的影响

研究发现,新冠肺炎疫情期间,英国急性冠状动脉综合征患者入院治疗人数大幅减少,虽然到2020年5月底,这一数字已部分逆转,但在此期间入院人数的减少可能导致院外患者死亡和心肌梗死并发症风险增加

EuroIntervention:肥胖悖论——BMI的适度增加与PCI后患者生存率的改善相关

本研究旨在评估接受经皮血管重建术的冠状动脉疾病患者的体重指数(BMI)与结局之间的关系。

NEJM:稳定性冠心病,该不该放支架?(ISCHEMIA研究)

2007年发表的COURAGE研究显示,在稳定性冠心病患者中,血运重建较最佳药物治疗(OMT)并无额外获益。对此,医学界存在一定的争议。在2019美国心脏协会科学年会(AHA 2019)期间,ISCH

Circulation:经皮冠状动脉介入治疗置入药物洗脱支架后的双重抗血小板治疗时间

经皮冠状动脉介入治疗(PCI)置入药物洗脱支架(DES)后双抗血小板治疗(DAPT)的最佳持续时间仍不确定。近日,心血管领域权威杂志Circulation上发表了一篇研究文章,研究人员比较了 PCI置